Article Correctness Is Author's Responsibility: Fingolimod Significantly Improves Quality of Life in Pediatric MS

The article below may contain offensive and/or incorrect content.

The phase 3 PARADIGMS trial involving 215 pediatric patients demonstrated superior efficacy for fingolimod over interferon beta-1a.